RxDoctor Payments Data

Kimberly Ebrahimi, APRN

Family · Las Vegas, NVNPI 1154016996

Payments from drug & device makers

$1,200in general payments, 2019–2025

Across 44 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$243
  • Lilly USA, LLC$194
  • Novo Nordisk$147
  • Bayer$113
  • Pfizer$99
  • AstraZeneca$91
  • plus $312 from 11 others

What the payments were for

  • Food & beverage$1,18499%
  • Entertainment$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,200 in reported general payments places this provider in the 70th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$1,316
Medicare patients
15
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$46,956
JardianceEmpagliflozin12$20,926
MounjaroTirzepatide15$19,008
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,344
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,154
Albuterol Sulfate HfaAlbuterol Sulfate49$1,369
Atorvastatin Calcium86$961
Gabapentin30$783
Levothyroxine Sodium36$741
ClopidogrelClopidogrel Bisulfate29$596
Amlodipine Besylate75$588
Tamsulosin Hcl28$535
Sertraline Hcl21$414
ValacyclovirValacyclovir Hcl12$378
Allopurinol21$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$46,95626 claims
Lilly USA, LLCMounjaro$194$19,00815 claims
AstraZenecaBreztri Aerosphere$91$6,34411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →